Shin Nippon Biomedical Laboratories, Ltd. · TSE:2395

Shin Nippon Biomedical Laboratories — Q1 FY2023/3 Earnings Presentation

10 slides from Shin Nippon Biomedical Laboratories's earnings presentation, Jul 29, 2022

  1. Slide 1: Presentation Materials on 1Q Financial Results

    The Fiscal Year Ending March 31, 2023 Presentation Materials on 1Q Financial Results July 29, 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. （TSE PRIME: 2395） Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.

  2. Slide 2: 1. Outline of 1Q Consolidated Financial Results

    1. Outline of 1Q Consolidated Financial Results Copyright© Copyright© 2022 2022 SHIN SHIN NIPPON NIPPON BIOMEDICAL BIOMEDICAL LABORATORIES, LABORATORIES, LTD. LTD. All All rights rights reserved. reserved. 1

  3. Slide 3: FY2023/3 1Q Consolidated Financial Results Highlights

    FY2023/3 1Q Consolidated Financial Results Highlights (100 million of yen) 2023年3月期 FY2023/3 Ordinary １Q Revenue Profit 1Q実績 前年同期比 Yoy Results 売上高 Revenue 40.4 +10.0 33.1% 営業利益 Operating Profit 7.1 +2.2 45.2% 経常利益 Ordinary Profit 27.7 +20.9 312.1% 40.4 経常利益 Ordinary Profit 10.8 +4.1 61.4% (excl. FX

  4. Slide 4: Yoy Comparison of 1Q Consolidated Operating P/L

    Yoy Comparison of 1Q Consolidated Operating P/L CRO事業 CRO business トランス Medipolis メディポリス 営業利益 Operating Translational business (Power profit レーショナル Research 事業 その他 Other 合計 Generation & total 前臨床事業 Clinical 国内臨床事業 リサーチ事業 business （発電・ホテル） Preclinical Hospitality) (Japan) 2023年3月期実績１Ｑ 1Q FY2022/3 9.0

  5. Slide 5: Yoy Comparison of 1Q Consolidated Ordinary P/L

    Yoy Comparison of 1Q Consolidated Ordinary P/L Medipolis Ordinary CROCRO事業 business トランス Translational メディポリス business Foreign 経常利益 profit レーショナル Research 事業 (Power 為替差損益 exchange その他 Other 合計 total 国内臨床事業 Clinical (incl. リサーチ事業 business （発電・ホテル） 前臨床事業 Preclinical Generation & gain and loss (新日本科学PP

  6. Slide 6: 2. Revision of Financial Forecast for FY2023/3

    2. Revision of Financial Forecast for FY2023/3 Copyright© Copyright© 2022 2022 SHIN SHIN NIPPON NIPPON BIOMEDICAL BIOMEDICAL LABORATORIES, LABORATORIES, LTD. LTD. All All rights rights reserved. reserved. 5

  7. Slide 7: FY2023/3 Forecast Revision

    FY2023/3 Forecast Revision Revenue and all profits are upwardly revised in view of various factors including the acquisition of Ina Research Inc. and its goodwill amortization impacts, and recent foreign exchange and currency trends. <FY2023/3 forecast keypoints> 1. Revenue （100 million of yen） Sale

  8. Slide 8: 3. References

    3. References Copyright© Copyright© 2022 2022 SHIN SHIN NIPPON NIPPON BIOMEDICAL BIOMEDICAL LABORATORIES, LABORATORIES, LTD. LTD. All All rights rights reserved. reserved. 7

  9. Slide 9: CRO Business: Contracts in Preclinical Services in 1Q FY2023/3

    CRO Business: Contracts in Preclinical Services in 1Q FY2023/3 Contract Backlog Amount (x100M JPY) (x100M JPY) 国内受注高 Contracts Received (Japan) 225.8 100.0 海外受注高(海外受注比率) Contracts Received (Overseas)(%) 220.0 受注残高 Backlog 200.0 80.0 167.1 180.0 160.0 60.0 140.0 123.6 119.8 16.1 26.8 120.0 (26.3％) (4

  10. Slide 10: Cautionary Notes

    Cautionary Notes 1. Projected results are based on information available to the Company at the time of writing, as well as certain assumptions judged by the Company to be reasonable. Various risks and uncertain factors could cause actual results to differ materially from these projections. This mate

Shin Nippon Biomedical Laboratories — Q1 FY2023/3 Earnings Presentation on 6ix